GENEVA, Sept. 16 (GenomeWeb News) - PerkinElmer is "highly interested" in investing in its cell-based assay and reagent businesses, and will likely attempt to obtain core competencies in these areas through acquisition, partnerships, or both in the coming year, a PerkinElmer official said at the Society for Biomolecular Screening conference here this week.


To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.